Polyphor, which has collaboration agreements in place with multiple pharmaceutical companies, raised $155m when it floated on the SIX Swiss Exchange.
Polyphor, a Switzerland-based biopharmaceutical company backed by multiple healthcare corporates, listed on the SIX Swiss Exchange yesterday after pricing its shares at CHF38 ($38) each.
The company has raised $155m in proceeds which could increase to $165m if underwriters fully exercise their over-allotment option. Its shares briefly rose to $40, though at the time of writing they are trading for CHF37.45.
Polyphor is working on drugs addressing antibiotic resistance and respiratory diseases. Its lead asset, Murepavadin, is currently in phase…
